2000 SIERRA POINT PARKWAY, BRISBANE, CA
Departure of Principal Financial Officer; Nicholas Rossettos Appointed CFO
Material disclosure
Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Enters $50 Million Purchase Agreement with Lincoln Park
Announces Development Collaboration for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Submission of Matters to a Vote of Security Holders
Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
S-8 POS
Correspondence
Submission Upload